| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Rejhan Idrizi, Peter Malcolm, Cynthia Shannon Weickert, Katerina Zavitsanou, Suresh Sundra. Striatal but not frontal cortical up-regulation of the epidermal growth factor receptor in rats exposed to immune activation in utero and cannabinoid treatment in adolescence. Psychiatry research. vol 240. 2017-02-21. PMID:27138815. |
in utero maternal immune activation (mia) and cannabinoid exposure during adolescence constitute environmental risk factors for schizophrenia. |
2017-02-21 |
2023-08-13 |
rat |
| Johannes Rentzsch, Ada Stadtmann, Christiane Montag, Hagen Kunte, Doris Plöckl, Rainer Hellweg, Jürgen Gallinat, Golo Kronenberg, Maria Christiane Jockers-Scherüb. Attentional dysfunction in abstinent long-term cannabis users with and without schizophrenia. European archives of psychiatry and clinical neuroscience. vol 266. issue 5. 2017-02-03. PMID:26182894. |
however, cannabis use may lead to different cognitive sequelae in patients with schizophrenia and in healthy controls, possibly reflecting preexisting alterations in the endocannabinoid system in schizophrenia. |
2017-02-03 |
2023-08-13 |
Not clear |
| Anna Capasso, Eduardo Sobarzo-Sánchez, Seyed Fazel Nabavi, Luca Rastrell. Cannabinoids for the Treatment of Schizophrenia: An Overview. Current topics in medicinal chemistry. vol 16. issue 17. 2017-02-01. PMID:26845552. |
cannabinoids for the treatment of schizophrenia: an overview. |
2017-02-01 |
2023-08-13 |
Not clear |
| Anna Capasso, Eduardo Sobarzo-Sánchez, Seyed Fazel Nabavi, Luca Rastrell. Cannabinoids for the Treatment of Schizophrenia: An Overview. Current topics in medicinal chemistry. vol 16. issue 17. 2017-02-01. PMID:26845552. |
cannabinoids treatments are both able to reduce the typical symptoms of schizophrenia and to slow down the disease aggravation. |
2017-02-01 |
2023-08-13 |
Not clear |
| Oualid Abboussi, Nadia Said, Karim Fifel, Sara Lakehayli, Abdelouahhab Tazi, Soumaya El Ganoun. Behavioral effects of D3 receptor inhibition and 5-HT4 receptor activation on animals undergoing chronic cannabinoid exposure during adolescence. Metabolic brain disease. vol 31. issue 2. 2017-01-10. PMID:26497809. |
chronic exposure to cannabinoids during adolescence results in long-lasting behavioral deficits that match some symptomatologic aspects of schizophrenia. |
2017-01-10 |
2023-08-13 |
Not clear |
| Alexandre Seillier, Andrea Giuffrid. Disruption of social cognition in the sub-chronic PCP rat model of schizophrenia: Possible involvement of the endocannabinoid system. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 26. issue 2. 2016-12-13. PMID:26706691. |
disruption of social cognition in the sub-chronic pcp rat model of schizophrenia: possible involvement of the endocannabinoid system. |
2016-12-13 |
2023-08-13 |
rat |
| Yong Li, Jimok Ki. CB2 Cannabinoid Receptor Knockout in Mice Impairs Contextual Long-Term Memory and Enhances Spatial Working Memory. Neural plasticity. vol 2016. 2016-11-04. PMID:26819779. |
cb2 cannabinoid receptors are primarily involved in immune functions, but also implicated in psychiatric disorders such as schizophrenia and depression. |
2016-11-04 |
2023-08-13 |
mouse |
| David D Aguilar, Andrea Giuffrida, Daniel J Lodg. THC and endocannabinoids differentially regulate neuronal activity in the prefrontal cortex and hippocampus in the subchronic PCP model of schizophrenia. Journal of psychopharmacology (Oxford, England). vol 30. issue 2. 2016-10-31. PMID:26510449. |
such information is important for understanding why marijuana and synthetic cannabinoid use may be contraindicated in schizophrenia patients while endocannabinoid enhancement may provide a novel therapeutic approach. |
2016-10-31 |
2023-08-13 |
rat |
| David W Volk, David A Lewi. The Role of Endocannabinoid Signaling in Cortical Inhibitory Neuron Dysfunction in Schizophrenia. Biological psychiatry. vol 79. issue 7. 2016-10-28. PMID:26210060. |
the role of endocannabinoid signaling in cortical inhibitory neuron dysfunction in schizophrenia. |
2016-10-28 |
2023-08-13 |
human |
| David W Volk, David A Lewi. The Role of Endocannabinoid Signaling in Cortical Inhibitory Neuron Dysfunction in Schizophrenia. Biological psychiatry. vol 79. issue 7. 2016-10-28. PMID:26210060. |
in addition, how interactions between these alterations in the endocannabinoid system and those in other inhibitory neurons in the prefrontal cortex in subjects with schizophrenia might increase the liability to adverse outcomes with cannabis use is considered. |
2016-10-28 |
2023-08-13 |
human |
| F Markus Leweke, Juliane K Mueller, Bettina Lange, Cathrin Rohlede. Therapeutic Potential of Cannabinoids in Psychosis. Biological psychiatry. vol 79. issue 7. 2016-10-28. PMID:26852073. |
over recent years, the interest in the endocannabinoid system (ecs) as a new target for the treatment of schizophrenia has evolved. |
2016-10-28 |
2023-08-13 |
Not clear |
| Mohamed Sherif, Rajiv Radhakrishnan, Deepak Cyril D'Souza, Mohini Ranganatha. Human Laboratory Studies on Cannabinoids and Psychosis. Biological psychiatry. vol 79. issue 7. 2016-10-28. PMID:26970363. |
randomized, double-blind, placebo-controlled, crossover laboratory studies demonstrate that cannabinoid agonists, including phytocannabinoids and synthetic cannabinoids, produce a wide range of positive, negative, and cognitive symptoms and psychophysiologic deficits in healthy human subjects that resemble the phenomenology of schizophrenia. |
2016-10-28 |
2023-08-13 |
human |
| Mohamed Sherif, Rajiv Radhakrishnan, Deepak Cyril D'Souza, Mohini Ranganatha. Human Laboratory Studies on Cannabinoids and Psychosis. Biological psychiatry. vol 79. issue 7. 2016-10-28. PMID:26970363. |
the magnitude of effects is similar to the effects of ketamine but qualitatively distinct from other psychotomimetic drugs, including ketamine, amphetamine, and salvinorin a. cannabinoid agonists have also been shown to transiently exacerbate symptoms in individuals with schizophrenia in laboratory studies. |
2016-10-28 |
2023-08-13 |
human |
| Mohamed Sherif, Rajiv Radhakrishnan, Deepak Cyril D'Souza, Mohini Ranganatha. Human Laboratory Studies on Cannabinoids and Psychosis. Biological psychiatry. vol 79. issue 7. 2016-10-28. PMID:26970363. |
patients with schizophrenia are more vulnerable than healthy control subjects to the acute behavioral and cognitive effects of cannabinoid agonists and experience transient exacerbation of symptoms despite treatment with antipsychotic medications. |
2016-10-28 |
2023-08-13 |
human |
| E Appiah-Kusi, E Leyden, S Parmar, V Mondelli, P McGuire, S Bhattacharyy. Abnormalities in neuroendocrine stress response in psychosis: the role of endocannabinoids. Psychological medicine. vol 46. issue 1. 2016-09-27. PMID:26370602. |
the aim of this article is to summarize current evidence regarding alterations in the neuroendocrine stress response system and endocannabinoid system and their relationship in psychotic disorders such as schizophrenia. |
2016-09-27 |
2023-08-13 |
human |
| E Appiah-Kusi, E Leyden, S Parmar, V Mondelli, P McGuire, S Bhattacharyy. Abnormalities in neuroendocrine stress response in psychosis: the role of endocannabinoids. Psychological medicine. vol 46. issue 1. 2016-09-27. PMID:26370602. |
recently the cannabinoid hypothesis of schizophrenia has emerged as a potential line of enquiry. |
2016-09-27 |
2023-08-13 |
human |
| E Appiah-Kusi, E Leyden, S Parmar, V Mondelli, P McGuire, S Bhattacharyy. Abnormalities in neuroendocrine stress response in psychosis: the role of endocannabinoids. Psychological medicine. vol 46. issue 1. 2016-09-27. PMID:26370602. |
future studies need to simultaneously investigate hpa axis and endocannabinoid alterations both at baseline and following experimental perturbation in healthy individuals and those with psychosis to understand how they interact with each other in health and disease and obtain mechanistic insight as to their relevance to the pathophysiology of schizophrenia. |
2016-09-27 |
2023-08-13 |
human |
| Fernanda F Peres, Raquel Levin, Valéria Almeida, Antonio W Zuardi, Jaime E Hallak, José A Crippa, Vanessa C Abili. Cannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia Pharmacotherapy. Frontiers in pharmacology. vol 7. 2016-09-26. PMID:27667973. |
cannabidiol, among other cannabinoid drugs, modulates prepulse inhibition of startle in the shr animal model: implications for schizophrenia pharmacotherapy. |
2016-09-26 |
2023-08-13 |
rat |
| Fernanda F Peres, Raquel Levin, Valéria Almeida, Antonio W Zuardi, Jaime E Hallak, José A Crippa, Vanessa C Abili. Cannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia Pharmacotherapy. Frontiers in pharmacology. vol 7. 2016-09-26. PMID:27667973. |
recent data point to the participation of the endocannabinoid system in the pathophysiology and pharmacotherapy of schizophrenia. |
2016-09-26 |
2023-08-13 |
rat |
| Marc W Manseau, Donald C Gof. Cannabinoids and Schizophrenia: Risks and Therapeutic Potential. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. vol 12. issue 4. 2016-07-22. PMID:26311150. |
cannabinoids and schizophrenia: risks and therapeutic potential. |
2016-07-22 |
2023-08-13 |
human |